Diabetic patients taking Invokana, Farxiga, or Jardiance are on alert over reports that these SGLT2 inhibitors could possibly cause a potentially lethal flesh-eating infection of the genitals. Bloomberg recently reported that SGLT2 inhibitor-induced Fourneir’s gangrene was observed in a dozen patients between March 2013 and May 2018. All cases required surgery and in one case the condition proved fatal. The FDA has said that more ...
Diabetes Drug Linked to Flesh-Eating Genital Infection
Posted September 25, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls
Patients taking Invokana and other SGLT2 inhibitors to treat and control their Type II diabetes have done so with the risk of a wide variety of adverse side effects for quite some time. The drugs’ links to serious conditions like bone fractures, kidney failure, and a particularly dangerous condition known as ketoacidosis are well established. They can strike anyone – young, old, men, and women.
However, there is read more.... --> continue reading...
Known as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.
Unfortunately, this relatively new class of drugs has already allegedly caused enough ...
continue reading...Invokana May Actually Increase Risk of Diabetes Amputations
Posted June 3, 2016 in Product News and Recalls
The effects of diabetes on a patient’s body are numerous and wide-ranging. In some cases, the inability to regulate insulin production is the only impact and is resolved in a seemingly simple way. Injection, diet, or an insulin pump that be used to take over sugar regulation for the diabetic. In other cases, however, the patient’s battle is an arduous one and strict compliance with physicians’ instructions is the ...
Lopez McHugh Files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury
Posted December 11, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
PHILADELPHIA (December 2015) – The national trial lawyers of Lopez McHugh have filed a lawsuit against Johnson & Johnson and its subsidiary, Janssen, alleging that its diabetes medication, Invokana®, causes patients to develop diabetic ketoacidosis.
The lawsuit (Case No. 15-12-00653) was filed in the Court of Common Pleas, Philadelphia County, and includes allegations that the manufacturers of Invokana knew that the drug could cause diabetic ketoacidosis but failed to warn doctors.
Diabetic ketoacidosis is a condition where the body produces ketones, ...
continue reading...Invokana Class-Action Lawsuit Filed in Canada
Posted November 1, 2015 in Product News and Recalls
The diabetes drug Invokana has become the focus of a national class-action lawsuit in Canada, CBC Nova Scotia reports. According to a statement filed in the Ontario Supreme Court of Justice, the lead plaintiff alleges that Janssen Pharmaceuticals’ new sodium-glucose cotransporter-2 (SGLT2) inhibitor was responsible for her kidney failure.
SGLT2 inhibitors, a new line of type 2 diabetes medications, work by directing excess blood sugars to be eliminated through urine. But not long after they reached the ...
continue reading...
